Sai Life Sciences Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/b59rgz9htsgnv86x0hyhkkkl.pdf

Key Takeaways


Strategic Integrated Engagements

Krishna Kanumuri: "I think the important thing here... to look at is the fact that we are the only company which has significant scale in all three dimensions, so discovery, development, and commercial."

Capacity Expansion & Capex

Siva Chittor: "This business is a service business unless you put up capacity and unless you're available and be ready, customers will move up their products from a clinical phase to some other supplier in commercial. What you will get to hear is potentials and possibilities."

Pipeline & Portfolio Progression


New Modalities


Demand Environment & End-Market Dynamics

Krishna Kanumuri: "India was a more of a tactical supplier where they would come for some projects. But now almost every large pharma is thinking about how do you become strategic with a few, maybe one or two companies in India."

AI & Discovery Services

Krishna Kanumuri: "I think AI impact on discovery services will not be significant, because end of the day, I think no matter what the design is, you have to continue to make the molecules and test the molecules."

Guidance & Commitments

CommitmentSpecificsTimeline
Bidar capacity revenue contributionExpanded 220 KL capacity to be revenue-accretiveFY27
Second 225 KL block commissioningNow expected early Q3 FY28; no impact on FY28 revenue commitmentsEarly Q3 FY28
Telangana greenfield ground-breakingDesign work commenced; ground-breaking expectedQ4 FY27 (Jan/Feb)
FY27 capex plan₹1,100–₹1,300 crores; ₹621 crores incurred in H1FY27
Second-half performanceStronger H2 expected; historical 40:60 H1/H2 splitH2 FY27
Capex fundingWill not starve business of capex; will use leverage, debt, or market if neededOngoing
New modalities migrationGradual shift over two to three years as customers gain comfort2–3 years

Key Metrics

MetricQ2 FY27
Revenue growth23% YoY
CDMO business growth20% YoY
CRO business growth28% YoY
H1 FY27 revenue growth17% YoY
H1 FY27 revenue splitCRO 38%, CDMO 62%
EBITDA margin28% of revenue, in line with YoY margin trajectory
H1 FY27 EBITDA margin28%
Q2 FY27 capex incurred₹358 crores
H1 FY27 capex incurredapproximately ₹621 crores
FY27 capex plan₹1,100 crores–₹1,300 crores
Headcountaround 4,400 at end of September
Active NCE molecules34, up from 33 last quarter; one molecule moved from late phase to commercial
Late-phase pipeline14 programs, net addition from 11 to 14 from Q1 to Q3
Commercial molecules34 programs
Large pharma clients19 out of 25
Largest customer concentrationaround 12% of revenue at end of last year
CDMO capacity utilization67% in Q2
Expanded manufacturing capacity at Bidararound 220 KL, ready; final quality trials underway
Additional capacity commissioning225 KL now expected by early Q3 FY28, moved from Q4 FY27
CRO pharma split40% as of end of 2026
Molecules taken from discovery to market5
Returning customer revenueover 90% of revenues
Cash reservesclose to ₹100 crores
Internal accrual₹400 crores–₹500 crores
Staff turnoverabout a fifth each year